Eckert & Ziegler SE
0NZY.IL
International Order Book13.39
EUR
-0.36
- -
ISIN
DE0005659700
Return %
Stock
S&P500
1Y
-27.03
19.43
3Y
37.90
76.01
5Y
-63.84
74.94
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Harald Hasselmann
- Full Time Employees
- 1,116
- Sector
- Healthcare
- Industry
- Medical - Specialties
- Address
- Robert-Rössle-Strasse 10 Berlin BE Germany 13125
- IPO Date
- Dec 21, 2010
- Website
- ezag.de
- Similar Companies
- Business
- Eckert & Ziegler SE is a Germany-based specialized radiopharmaceutical company that develops, manufactures, and distributes diagnostic and therapeutic radiopharmaceutical products for the medical and research sectors, with a focus on oncology, cardiology, neuroscience, and molecular imaging applications. The company operates through production facilities and sales offices across Europe, the United States, and other regions, delivering a broad portfolio of products and services to hospitals, clinics, and research institutions. Main products and services: - Diagnostic radiopharmaceuticals for positron emission tomography and single-photon emission computed tomography imaging; includes established radiotracers and in-house development programs; provides kits, ready-to-use formulations, and custom labeling services - Therapeutic radiopharmaceuticals for targeted internal radiation therapy; includes beta- and alpha-emitting compounds, radiopharmaceuticals, and related dosimetry and patient-specific treatment planning support - Radiopharmaceutical manufacturing and contract development services; including GMP production of radioisotopes, radiopharmacy manufacturing, quality control testing, regulatory support, and batch release services - Research and development services; early-stage program support, radiochemistry expertise, preclinical and translational research collaboration, and credentialed access to radiopharmaceuticals for clinical trials - Imaging services and clinical support; radiopharmacology consulting, imaging protocol design, and patient management guidance for diagnostic and therapeutic procedures - Aftermarket and technical support; spare parts, maintenance, service contracts, calibration, and compliance assistance Latest major company changes: - Strategic partnerships and collaborations with pharmaceutical and academic partners to broaden radiopharmaceutical portfolio and accelerate late-stage development - Acquisitions or stake acquisitions that expand manufacturing capacity, geographic reach, or pipeline assets - Launch of new radiopharmaceutical products or expanded indications for existing products - Organizational restructuring or rebranding efforts to optimize global operations and regionalgo-to-market strategies - Expansion of production facilities or modernization of GMP-compliant manufacturing lines to meet rising demand - Reorganization of subsidiary entities to streamline corporate structure and align with strategic priorities Additional context: - Industry: Radiopharmaceuticals, diagnostic and therapeutic nuclear medicine - Segments: Manufacturing and sale of radiopharmaceuticals; clinical support services; contract development and manufacturing - Target markets: Hospitals, clinics, university medical centers, research institutions, and contract research organizations - Geographic operations: Europe (Germany headquarters and key facilities), North America, and other international markets - Founding year: 1997 - Headquarters: Berlin, Germany - Subsidiaries/parent: Operates as Eckert & Ziegler SE with several regional subsidiaries and distribution partners; belongs to a corporate group focused on radiopharmaceuticals and nuclear medicine research and applications